Tocilizumab (Actemra, RoActemra)

Description

Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor and is primarily used in colorectal cancer for managing immune-related adverse events rather than direct anti-tumor therapy. In the CRC setting, it serves as a therapeutic intervention for checkpoint inhibitor-induced colitis and other inflammatory complications that can arise during immunotherapy treatment. This IL-6 receptor antagonist helps control severe inflammatory responses while allowing patients to continue or resume their primary cancer treatment regimen.

Mechanism of Action

Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors, blocking IL-6-mediated signaling pathways that drive inflammatory responses. By inhibiting IL-6 signaling, it reduces the production of inflammatory cytokines and helps resolve immune-mediated tissue damage, particularly in the gastrointestinal tract during checkpoint inhibitor-induced colitis.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials